CRM
XBI icon

Cramer Rosenthal McGlynn’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cramer Rosenthal McGlynn’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-56,624
Closed -$5.25M – 110
2024
Q2 		$5.25M Buy
56,624
+6,706
+13% +$601K 0.31% 89
2024
Q1 		$4.74M Buy
49,918
+17,675
+55% +$1.64M 0.26% 88
2023
Q4 		$2.88M Buy
+32,243
New +$2.39M 0.16% 95

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Cramer Rosenthal McGlynn's XBI Position: Q3 2024 in Review

Cramer Rosenthal McGlynn sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 56,624 shares — an estimated $5.25M sold.

Cramer Rosenthal McGlynn first reported a position in XBI in Q4 2023 and held it in 3 quarters. The position peaked at $5.25M in Q2 2024. 770 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

  • Cramer Rosenthal McGlynn reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 56,624 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $5.25M.
  • Cramer Rosenthal McGlynn first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and held it in 3 quarters.
  • Cramer Rosenthal McGlynn's State Street SPDR S&P Biotech ETF position peaked at $5.25M in Q2 2024.
  • 770 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Cramer Rosenthal McGlynn's 13F filing for Q3 2024, filed 14 Nov 2024.